The Wistar Institute scientists have discovered a new approach to treating ovarian cancer that, in preclinical laboratory testing, shrinks tumors and improves survival rates while simultaneously making tumors more receptive to chemotherapy treatment.
A collaboration between The Wistar Institute and the University of Buea in Cameroon has uncovered the mechanisms for a medicinal plant with anti-HIV potential in Croton oligandrus Pierre & Hutch, a species of African tree that has been used in traditional healing in Cameroon to treat a variety of diseases and conditions including cancers and diabetes.
The Wistar Institute’s Hubert J.P. Schoemaker Education and Training Center was the recipient of a $100,000 eXperience grant from NIIMBL to support an immersive weeklong training program at the Institute.
New research from the Salvino lab identifies novel series of MPro inhibitors
Wistar scientists have demonstrated the role of Parkin — a protein implicated in Parkinson's disease — in the body’s innate immune response to cancer.
Wistar Institute scientists have successfully isolated and cloned fully human antibodies that can block specific Type-I interferon molecules in vitro; their discovery has an array of potential clinical & research applications, enabling scientists with a new way to investigate the role of specific Type-I interferons in a variety of diseases.
The Wistar Institute and Wexford Science & Technology, LLC, announced that Wistar has signed a lease for new laboratory and office space at uCity Square in Philadelphia to expand its capacity and resources essential for making groundbreaking discoveries that advance human health.
Wistar Celebrates Accomplishments of 58 Diverse, Next-Gen Students & Pre-apprentices Completing Summer Science Education & Training Programs.
Wistar Institute honors 2023 Nobel laureate Katalin Karikó, Ph.D., as the 2024 Helen Dean King Award recipient on October 8, 2024 at noon (ET).
July 16th at 6:30 pm EDT, Nobel Laureate in Medicine or Physiology Drew Weissman, M.D., Ph.D., delivers the 28th annual Jonathan Lax Memorial Lecture at The Wistar Institute in recognition of his outstanding contributions to HIV research.
The Wistar Institute is pleased to announce a research collaboration with Accelerated Biosciences Corp. aimed at creating a platform based on human trophoblast stem cells to explore new immunotherapies that use Accelerated Bio’s proprietary technology.
Jozef Madzo, Ph.D., recruited as an assistant professor and director of Bioinformatics, at The Wistar Institute.
The Wistar Institute's Dr. Noam Auslander was awarded a $600,000 Women Scientists Innovation Award for Cancer Research grant from the V Foundation for Cancer Research to support the next three years of her research, which will use proteins of gut bacteria to predict immunotherapy benefit in melanoma.
Wistar scientists have built upon BTE technology to develop new and improved recombinant and synthetic DNA versions of therapeutic antibodies that target CA9, called Persistent Multivalent T Cell Engager (CA9-PMTE), that shows promise in pre-clinical models as a potent, long-lasting treatment against ccRCC.
Wistar Institute’s Paul M. Lieberman, Ph.D., and lab, have demonstrated how B cells infected with the Epstein-Barr virus (EBV) can contribute to a pathogenic, inflammatory phenotype that contributes to multiple sclerosis (MS); the group has also shown how these problematic B cells can be selectively targeted in a way that reduces the damaging autoimmune response of multiple sclerosis.
Wistar was awarded a $649,971 grant from the National Science Foundation (NSF) to support the continued expansion of its award-winning Biomedical Technician Training (BTT) Pre-apprenticeship Program.
The Wistar Institute assistant professor Dr. Filippo Veglia has discovered a key mechanism of how glioblastoma — a serious and often fatal brain cancer — suppresses the immune system so that the tumor can grow unimpeded by the body’s defenses.
Results of a new clinical trial published in Nature Medicine show that a novel, personalized neoantigen vaccine therapy demonstrated promising anti-tumor efficacy in patients with liver cancer who failed their original front-line treatment. The foundational biomedical research leading to this important study and important outcome originated from research in the Vaccine & Immunotherapy Center at The Wistar Institute.
Wistar's Dr. Abdel-Mohsen has identified sugar abnormalities in the blood that may promote biological aging and inflammation in people living with HIV.
The Wistar Institute Appoints Max Berger to its Board of Trustees
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right